Camila Barbosa Lyra Oliveira

Dr. Camila Barbosa Lyra Oliveira

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
CLCamilla de Lima
Camilla de Lima
GVGisele Vajgel
Gisele Vajgel
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Lupus nephritis (LN) is the most frequent and severe of systemic lupus erythematosus (SLE) clinical manifestations and contributes to the increase of morbidity and mortality of patients due to chronic kidney disease. The NLRP3 (NLR pyrin domain containing 3) is a member of the NLR (NOD-like receptors), and its activation results in the production of pro-inflammatory cytokines, which can contribute to the pathogenesis of LN. In this review manuscript, we approach the relation between the NLRP3 inflammasome, SLE, and LN, highlighting the influence of genetic susceptibility of NLRP3 polymorphisms in the disease; the main functional studies using cellular and animal models of NLRP3 activation; and finally, some mechanisms of NLRP3 inhibition for the development of possible therapeutic drugs for LN.

15 November 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
GVGisele Vajgel
Gisele Vajgel
SLSuelen Cristina Lima
Suelen Cristina Lima
DSDiego Jeronimo S. Santana
Diego Jeronimo S. Santana
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCDenise Maria N. Costa
Denise Maria N. Costa
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
Objective.: Apolipoprotein L1 gene (APOL1) G1 and G2 renal risk alleles (RRA) are associated with endstage renal disease in blacks with lupus nephritis (LN). The present study determined frequencies ofAPOL1RRA in nonwhite Brazilian patients with LN and controls to assess association with renal outcomes.Methods.: APOL1 RRA were genotyped in 222 healthy blood donors (controls) and 201 cases with LN from 3 outpatient clinics. Two single-nucleotide polymorphisms in the G1 (rs73885319 and rs60910145) and an indel for the G2 (rs71785313) variant were genotyped.Results.: The frequency ofAPOL1RRA in nonwhite Brazilian LN cases did not differ significantly from healthy controls, and few participants had 2 RRA. In the sample, 84.6% of LN cases and 84.2% of controls had 0 RRA, 13.4% and 15.3% had 1 RRA, and 2.0% and 0.4% had 2 RRA, respectively. LN cases with ≥ 1APOL1RRA had similar baseline characteristics and renal responses to treatment, yet faced higher risk for progressive chronic kidney disease (CKD) to an estimated glomerular filtration rate < 30 ml/min/1.73 m2compared to those with 0 RRA (11.2% with 0, 29.6% with 1; 50% with 2 RRA, p = 0.005). Although glomerular lesions and activity scores on initial kidney biopsy did not differ significantly between individuals based onAPOL1genotype, chronicity scores, tubular atrophy, and interstitial fibrosis were more severe in those with ≥ 1 RRA (p = 0.011, p = 0.002, p = 0.018, respectively).Conclusion.: Although initial kidney lesions and treatment responses were similar, a singleAPOL1RRA in nonwhite Brazilians with LN was associated with increased risk of advanced CKD and possibly more tubulointerstitial damage.

6 October 2020 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
CLCamilla Albertina Dantas Lima
Camilla Albertina Dantas Lima
GVGisele Vajgel
Gisele Vajgel
ACAntonio Victor Campos Coelho
Antonio Victor Campos Coelho
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
Aims Hospitalised patients with COVID-19 have a variable incidence of acute kidney injury (AKI) according to studies from different nationalities. The present systematic review and meta-analysis describes the incidence of AKI, need for renal replacement therapy (RRT) and mortality among patients with COVID-19-associated AKI. Methods We systematically searched electronic database PubMed, SCOPUS and Web of Science to identify English articles published until 25 May 2020. In case of significant heterogeneity, the meta-analyses were conducted assuming a random-effects model. Results From 746 screened publications, we selected 21 observational studies with 15 536 patients with COVID-19 for random-effects model meta-analyses. The overall incidence of AKI was 12.3% (95% CI 7.3% to 20.0%) and 77% of patients with AKI were critically ill (95% CI 58.9% to 89.0%). The mortality among patients with AKI was 67% (95% CI 39.8% to 86.2%) and the risk of death was 13 times higher compared with patients without AKI (OR=13.3; 95% CI 6.1 to 29.2). Patients with COVID-19-associated AKI needed for RRT in 23.4% of cases (95% CI 12.6% to 39.4%) and those cases had high mortality (89%–100%). Conclusion The present study evidenced an incidence of COVID-19-associated AKI higher than previous meta-analysis. The majority of patients affected by AKI were critically ill and mortality rate among AKI cases was high. Thus, it is extremely important for health systems to be aware about the impact of AKI on patients’ outcomes in order to establish proper screening, prevention of additional damage to the kidneys and adequate renal support when needed.

4 December 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
GVGisele Vajgel
Gisele Vajgel
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCD M N Costa
D M N Costa
MCM A G M Cavalcante
M A G M Cavalcante
LVL M Valente
L M Valente
PSP Sandrin-Garcia
P Sandrin-Garcia
Objective: We analyzed baseline and follow-up characteristics related to poorer renal outcomes in a Brazilian cohort of admixture race patients with lupus nephritis. Methods: Overall, 280 outpatients with a diagnosis of systemic lupus erythematosus and previous kidney biopsy of lupus nephritis were recruited from August 2015 to December 2018 and had baseline laboratory and histologic data retrospectively analyzed; patients were then followed-up and data were recorded. The main outcome measure was the estimated glomerular filtration rate at last follow-up. Secondary analyses assessed the impact of initial kidney histology and treatment in long-term kidney survival. Results: Median duration of lupus nephritis was 60 months (interquartile range: 27–120); 40 (14.3%) patients presented progressive chronic kidney disease (estimated glomerular filtration rate <30 and ≥10 ml/min/1.73 m2) or end-stage kidney disease at last visit. Adjusted logistic regression analysis showed that class IV lupus nephritis (odds ratio 14.91; 95% confidence interval 1.77–125.99; p = 0.01) and interstitial fibrosis ≥25% at initial biopsy (odds ratio 5.87; 95% confidence interval 1.32–26.16; p = 0.02), lack of complete or partial response at 12 months (odds ratio 16.3; 95% confidence interval 3.74–71.43; p < 0.001), and a second renal flare (odds ratio 4.49; 95% confidence interval 1.10–18.44; p = 0.04) were predictors of progressive chronic kidney disease. In a Kaplan-Meier survival curve we found that class IV lupus nephritis and interstitial fibrosis ≥25% were significantly associated with end-stage kidney disease throughout follow-up (hazard ratio 2.96; 95% confidence interval 1.3–7.0; p = 0.036 and hazard ratio 4.96; 95% confidence interval 1.9–12.9; p < 0.0001, respectively). Conclusion: In this large cohort of admixture race patients, class IV lupus nephritis and chronic interstitial damage at initial renal biopsy together with non-response after 1 year of therapy and relapse were associated with worse long-term renal outcomes.

13 February 2018 in Nephron
Verified
Journal Article
Open access
PDF file
DCDENISE COSTA
DENISE COSTA
LVLucila Maria Valente
Lucila Maria Valente
GFGisele Vajgel Fernandes
Gisele Vajgel Fernandes
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
HCHeidi Lacerda Alves da Cruz
Heidi Lacerda Alves da Cruz
ESEmanuel Sávio Cavalcante Sarinho
Emanuel Sávio Cavalcante Sarinho
Background: Idiopathic membranous nephropathy (IMN) has been linked to the lectin pathway, IgG4 and genetic susceptibility. We investigated the frequency of mannose-binding lectin2 (MBL2) gene polymorphisms and the serum ratio of IgG4 in patients with membranous nephropathy (MN). Methods: Polymorphisms in the exon 1 of the MBL2 gene (codons 52, 54, and 57) and single base polymorphisms at positions –550 (HL) and –221 (XY) in the promoter region were evaluated in 60 patients compared to a control group (CG) of 101 blood donors. It established the frequency of polymorphisms and the serum ratio of IgG4 comparing 2 etiologies of MN: idiopathic (35 patients) and secondary to systemic lupus erythematosus (25 patients). Results: Patients with MN had a 2.54-fold higher probability (95% CI 1.51–4.31) of carrying the O alelle, exon 1 variant, and 11.16-fold higher probability (95% CI 4.77–28.41) of having A/O genotype when compared to CG. The frequency of polymorphisms in the promoter region was similar between the groups. Combined genotypes generally related to the defective production of MBL (YA/O, XA/O and O/O) were more frequent in patients with MN (OR 7.11; 95% CI 2.69–21.27), when compared to controls. The median of serum ratio IgG4 was 5% for idiopathic MN and 3% for lupus MN patients (p = 0.016). Conclusions: Our data suggests that MBL2 polymorphisms may be associated with the activation of the lectin pathway by IgG4 subclass antibodies in MN.

1 December 2025 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
GVGisele Vajgel
Gisele Vajgel
BJBraziliano Miguel da Silva Júnior
Braziliano Miguel da Silva Júnior
CFCarlos R Silva Miranda Filho
Carlos R Silva Miranda Filho
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
DCDenise Maria Do Nascimento Costa
Denise Maria Do Nascimento Costa
PSPaula Sandrin-Garcia
Paula Sandrin-Garcia
Background: Lupus nephritis (LN) patients under immunosuppression were excluded from the main trials with sodium–glucose co-transporter 2 inhibitors. This trial aims to analyse the effect and safety of dapagliflozin in inactive LN patients with residual proteinuria. Methods: We recruited adult LN patients (class III, IV(±V)] without activity, with proteinuria >500 mg/24 h and an estimated glomerular filtration rate (eGFR) ≥20 ml/min, on maintenance treatment with stable renin–angiotensin–aldosterone system inhibitors and mycophenolate mofetil ≤2 g/day. They were randomized to receive dapagliflozin on top of standard-of-care (SoC) therapy or not. After 6 months the groups were crossed over. The primary endpoint is a reduction of proteinuria compared with baseline (6 and 12 months). Results: From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6 months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. The mean age was 40.6 ± 12.3 years, 19 (90.5%) were female, none had diabetes and the mean body mass index was 26.1 ± 5.2. The final analysis showed a significant reduction in proteinuria of −36.1% in patients after 6 months of dapagliflozin as opposed to −3.5% for those in the SoC therapy group (P = .03). There were more reported hypotension symptoms in the dapagliflozin group [7 cases (33.3%)] but no drug withdrawal and no significant changes in blood pressure or weight in the follow-up between the groups. There was one case of urinary infection in each group, but in the same patient. Conclusions: We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.